论文部分内容阅读
对４０例Ⅲ期原发性肝癌进行了６３次肝动脉插管治疗。单纯化疗１０例，化疗（ＴＡＩ）＋碘化油栓塞（ＴＡＥ）３０例，其中１７例加用明胶海绵栓塞。栓塞３０例中，２４例肿瘤缩小，其中５例缩小５０％以上；未栓塞１０例中，仅２例略有缩小．ＡＦＰ增高的３５例中１８例下降（５１．４％）．治后ＴＡＥ３０例中存活＞６个月１４例（４６．７％）．＞１年５例（１６．７％）．ＴＡＩ１０例中仅１例存活＞６个月，无１例超过１年。结果表明：ＴＡＩ和ＴＡＥ是治疗晚期肝癌首选的方法，可以延长生存期，提高生活质量，对门脉癌栓作ＴＡＥ时要尽可能超选择，减少剩余肝组织的误栓。对Ａ－Ｖ分流病例，周围性栓塞与中央型栓塞同时进行，效果会更好。本文对插管治疗晚期肝癌的不足之处作了初步探讨。
Hepatic artery catheterization was performed in 63 cases of stage III primary liver cancer. There were 10 cases of chemotherapy alone, 30 cases of chemotherapy (TAI) and iodized oil embolism (TAE), of which 17 cases were embolized with gelatin sponge. Embolism in 30 cases, 24 cases of tumor shrinking, in which 5 cases reduced more than 50%; in 10 cases of non-embolization, only 2 cases slightly reduced. Among the 35 cases with increased AFP, 18 cases decreased (51.4%). After treatment, 30 cases of TAE survived >6 months in 14 cases (46.7%). >1 year in 5 cases (16.7%). Only 1 case of TAI survived >6 months and none of the cases exceeded 1 year. The results showed that: TAI and TAE are the preferred methods for the treatment of advanced hepatocellular carcinoma, which can prolong the survival period and improve the quality of life. When the portal vein tumor embolus is TAE, it should be selected as much as possible to reduce the miscarriage of the remaining liver tissue. In the case of A-V shunts, peripheral embolization and central embolization will be performed at the same time, and the effect will be better. This article discusses the inadequacy of intubation in the treatment of advanced liver cancer.